Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.72 |
| ▸ | SRC | P12931 | 2/20 | 0.71 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.68 |
| ▸ | AXL | P30530 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | KIT | P10721 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 1/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897489 | 0.89 | KDR (0.67) | KDRSRCTGFBR1PDGFRAAXL | |
| SCHEMBL3901030 | 0.86 | SRC (0.76) | KDRSRCTGFBR1PDGFRAAXL | |
| SCHEMBL3895885 | 0.86 | SRC (0.80) | KDRSRCTGFBR1PDGFRAKIT | |
| SCHEMBL2747336 | 0.85 | KDR (0.85) | KDRPDGFRAAXLCYP3A4CYP2D6 | |
| SCHEMBL2747247 | 0.84 | KDR (1.00) | KDRCYP3A4CYP2D6AURKALCK | |
| SCHEMBL3227406 | 0.84 | KDR (0.73) | KDRPDGFRAAXLKITAURKA | |
| SCHEMBL2747514 | 0.83 | KDR (0.74) | KDRPDGFRAAXLCYP3A4CYP2D6 | |
| SCHEMBL3894063 | 0.83 | SRC (1.00) | KDRSRCTGFBR1PDGFRAKIT | |
| SCHEMBL1471393 | 0.82 | KDR (0.71) | KDRPDGFRAAXLKITAURKA | |
| SCHEMBL4548871 | 0.82 | KDR (0.71) | KDRAXLCYP3A4CYP2D6AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-7560558-B2 | Compound having TGFβ inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-07-14 | — | — | US | disclosed |
| US-7560558-B2 | Compound having TGFβ inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-07-14 | — | — | US | disclosed |
| US-7560558-B2 | Compound having TGFβ inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1548008-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | TGFB1, TGFBR1, TGFBR2 | KDR 233/4885SRC 399/4885TGFBR1 2/4885 |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TGFB1, TGFBR1, TGFBR2 | KDR 356/4885SRC 496/4885TGFBR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.